Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Ian Wilson and Nicholas Wu.
Connection Strength

6.190
  1. A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. PLoS Pathog. 2020 12; 16(12):e1009089.
    View in: PubMed
    Score: 0.917
  2. An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain. Cell Rep. 2020 10 20; 33(3):108274.
    View in: PubMed
    Score: 0.905
  3. A complex epistatic network limits the mutational reversibility in the influenza hemagglutinin receptor-binding site. Nat Commun. 2018 03 28; 9(1):1264.
    View in: PubMed
    Score: 0.761
  4. Diversity of Functionally Permissive Sequences in the Receptor-Binding Site of Influenza Hemagglutinin. Cell Host Microbe. 2017 08 09; 22(2):247-248.
    View in: PubMed
    Score: 0.728
  5. In vitro evolution of an influenza broadly neutralizing antibody is modulated by hemagglutinin receptor specificity. Nat Commun. 2017 05 15; 8:15371.
    View in: PubMed
    Score: 0.716
  6. Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain. Nat Commun. 2021 06 21; 12(1):3815.
    View in: PubMed
    Score: 0.238
  7. Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. Science. 2021 08 13; 373(6556):818-823.
    View in: PubMed
    Score: 0.237
  8. A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. Cell Host Microbe. 2021 05 12; 29(5):806-818.e6.
    View in: PubMed
    Score: 0.235
  9. Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. Immunity. 2020 12 15; 53(6):1272-1280.e5.
    View in: PubMed
    Score: 0.229
  10. Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. Biochem Biophys Res Commun. 2021 01 29; 538:192-203.
    View in: PubMed
    Score: 0.227
  11. Structural basis of a shared antibody response to SARS-CoV-2. Science. 2020 08 28; 369(6507):1119-1123.
    View in: PubMed
    Score: 0.223
  12. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science. 2020 05 08; 368(6491):630-633.
    View in: PubMed
    Score: 0.219
  13. Antibody 27F3 Broadly Targets Influenza A Group 1 and 2 Hemagglutinins through a Further Variation in VH1-69 Antibody Orientation on the HA Stem. Cell Rep. 2017 Sep 19; 20(12):2935-2943.
    View in: PubMed
    Score: 0.183
  14. Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2. Cell Rep. 2021 05 11; 35(6):109109.
    View in: PubMed
    Score: 0.059
  15. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape. Science. 2021 02 12; 371(6530).
    View in: PubMed
    Score: 0.058
  16. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020 08 21; 369(6506):956-963.
    View in: PubMed
    Score: 0.055
  17. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections. Cell Rep. 2020 06 02; 31(9):107725.
    View in: PubMed
    Score: 0.055
  18. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections. Cell Rep. 2020 06 02; 31(9):107725.
    View in: PubMed
    Score: 0.055
  19. Structure-based optimization and synthesis of antiviral drug Arbidol analogues with significantly improved affinity to influenza hemagglutinin. Bioorg Med Chem Lett. 2017 08 15; 27(16):3744-3748.
    View in: PubMed
    Score: 0.045
  20. A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic ß-Hairpin Structure. Immunity. 2017 04 18; 46(4):690-702.
    View in: PubMed
    Score: 0.045
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.